Developing a synthetic lung surfactant for preterm infants
Preclinical Development of a ME-1001, a Synthetic Lung Surfactant
['FUNDING_SBIR_2'] · MOLECULAR EXPRESS, INC. · NIH-11086104
This study is testing a new treatment called ME-1001, a synthetic lung surfactant, to help preterm babies with respiratory distress syndrome breathe better and stay healthier.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MOLECULAR EXPRESS, INC. (nih funded) |
| Locations | 1 site (RANCHO DOMINGUEZ, UNITED STATES) |
| Trial ID | NIH-11086104 on ClinicalTrials.gov |
What this research studies
This research focuses on creating ME-1001, a synthetic lung surfactant designed to treat neonatal respiratory distress syndrome (NRDS) in preterm infants. NRDS is a serious condition caused by surfactant deficiency, leading to high rates of mortality and morbidity among affected infants. The study aims to demonstrate the effectiveness of ME-1001, which mimics natural surfactant proteins and lipids, in improving lung function and reducing complications associated with NRDS. By utilizing a fully synthetic approach, this research seeks to overcome supply limitations and cost issues associated with traditional animal-derived surfactants.
Who could benefit from this research
Good fit: Ideal candidates for this research are preterm infants, particularly those born at or before 37 weeks of gestation, who are at risk for neonatal respiratory distress syndrome.
Not a fit: Patients who are not preterm or do not have neonatal respiratory distress syndrome may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce mortality and morbidity rates in preterm infants suffering from neonatal respiratory distress syndrome.
How similar studies have performed: Previous research has shown that animal-derived surfactants have been effective in treating NRDS, but this synthetic approach is novel and aims to provide a more accessible alternative.
Where this research is happening
RANCHO DOMINGUEZ, UNITED STATES
- MOLECULAR EXPRESS, INC. — RANCHO DOMINGUEZ, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FUJII, GARY — MOLECULAR EXPRESS, INC.
- Study coordinator: FUJII, GARY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.